Novel agents in CML therapy: tyrosine kinase inhibitors and beyond

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Imatinib is a tyrosine kinase inhibitor effective against chronic myeloid leukaemia (CML).
• Emergence of imatinib resistance is a significant clinical challenge in CML treatment.
• Resistance mechanisms include BCR-ABL mutations, genomic amplification, transporter modulation, and Bcr-Abl-independent pathways.

Purpose of the Study:

• To review the current landscape of imatinib resistance in chronic myeloid leukaemia.
• To discuss novel therapeutic agents and strategies for overcoming imatinib resistance.
• To explore inhibitors targeting Bcr-Abl and downstream signaling pathways.

Main Methods:

• Literature review of existing studies on imatinib resistance in CML.
• Analysis of novel ATP-competitive and non-ATP-competitive Bcr-Abl tyrosine kinase inhibitors.
• Examination of inhibitors targeting downstream signaling pathways like Ras-Raf-MAPK and PI3K-Akt-mTOR.

Main Results:

• Point mutations in the Abl kinase domain are the most frequent cause of imatinib resistance.
• Genomic amplification of BCR-ABL and other mechanisms contribute to treatment failure.
• Numerous novel agents demonstrate efficacy against imatinib-resistant CML in preclinical and clinical studies.

Conclusions:

• Developing effective strategies against imatinib resistance is crucial for improving CML outcomes.
• Targeting Bcr-Abl directly and inhibiting downstream pathways offers promising therapeutic avenues.
• Further research into novel agents and combination therapies is warranted for persistent CML.